Dr. Melina Claussnitzer: Genetics, Causality, and Metabolic Disease

Dr. Claussnitzer’s research focuses on bridging metabolic disease genetics and causal target discovery. She pioneered the variants-to-function (V2F) framework, which systematically converts GWAS-associated risk loci into mechanistic insight using integrated experimental and computational approaches. Her work leverages large-scale human genetic data to identify and validate disease-driving targets for population-scale conditions such as obesity and type 2 diabetes. Her contributions span both fundamental biology and therapeutic translation, including service on the scientific advisory boards of biotechnology companies such as SixPeaks Bio (acquired by AstraZeneca).